Seatol-based biotech startup Lumane Bioscience A 30 million series has raised the C SE extension and has announced several updates on the leadership.
The Westriver Group led the latest fund, which raised the company’s total capital for $ 186.8 million.
The new investment will help lumen to accelerate the biological drug pipelines made from a type of blue-green algae made from engineering engineers.
Lumen’s technology platform enables therapeutic proteins-the Tradition is intentionally injected or infected-an edible, enables and distributes orally in the form of low prices.
The 5-person agency is targeting diseases that work or produce from the gastrointestinal tract. It recently reports the second results committed from LMN -20 to Lumne’s lead candidate LMN -20 C Infection
The company also announced that Jeff RikesFormer Microsoft President and CEO of the Gates Foundation joined the board of Lumen as an independent director.
Update to other staff:
- Eric AndersonThe founder and CEO of the Westriver Group, the Vice Chairman of the Board was elected.
- EVP from NHI Khung between internal promotions and Colery In the SVP, when the retired US Army Colonel and Clinical Trialist Dr. David Sanders joined the clinical development team.
The company has increased its workforce by about 40% since 2023 and introduced the second production facility.
Lumen is led by CEO Brian finoFormer Senior Vice President and Chief Science Officer of Adapted Biotechnologies Jim RobertsFred Hutchinson is a former head of Basic Science at the Cancer Research Institute. They were co-founded in startup in 2017.